Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Tăng mức độ yếu tố thần kinh có nguồn gốc từ não trong huyết tương liên quan đến hiệu quả của axit béo không bão hòa đa n−3 trong tâm thần phân liệt lần đầu: phân tích kết quả thứ cấp từ thử nghiệm lâm sàng ngẫu nhiên OFFER
Tóm tắt
Axit béo không bão hòa đa n−3 (n−3 PUFA) ảnh hưởng đến nhiều cơ chế sinh hóa được giả thuyết trong sinh bệnh học của tâm thần phân liệt, có thể ảnh hưởng đến việc tổng hợp BDNF. Một nghiên cứu ngẫu nhiên có đối chứng giả dược đã được thiết kế để so sánh hiệu quả của một can thiệp kéo dài 26 tuần bằng 2,2 g/ngày n−3 PUFA hoặc giả dược dầu ô liu, liên quan đến mức độ triệu chứng ở bệnh nhân tâm thần phân liệt lần đầu. Các chỉ số kết quả thứ cấp của nghiên cứu là mô tả mối liên hệ giữa hiệu quả lâm sàng của n−3 PUFA và sự thay đổi mức BDNF ngoại vi. Bảy mươi mốt bệnh nhân trong độ tuổi 16–35 đã tham gia nghiên cứu và được phân ngẫu nhiên vào các nhóm nghiên cứu: 36 vào nhóm EPA+DHA và 35 vào nhóm giả dược. Mức BDNF trong huyết tương được đánh giá ba lần, tại thời điểm ban đầu và vào tuần thứ 8 và 26 của can thiệp. Mức BDNF trong huyết tương được xác định trong các mẫu huyết tương bằng bộ thử nghiệm ELISA BDNF cho người của Quantikine. Sự thay đổi mức BDNF trong huyết tương được tương quan thêm với sự thay đổi mức độ triệu chứng trong các lĩnh vực lâm sàng khác nhau. Một sự tăng cường đáng kể về mức BDNF trong huyết tương được quan sát thấy trong can thiệp so với nhóm giả dược (Cohen’s d = 1.54). Sự thay đổi của mức BDNF có tương quan nghịch với sự thay đổi triệu chứng trầm cảm được đánh giá bằng Thang đo Đánh giá Trầm cảm Calgary ở Bệnh nhân Tâm thần phân liệt (Pearson’s r = −0.195; p = 0.018). Hiệu quả của can thiệp sáu tháng với n−3 PUFA được quan sát thấy ở bệnh nhân tâm thần phân liệt lần đầu có thể liên quan đến sự gia tăng mức BDNF, có thể được kích hoạt bởi sự kích hoạt các con đường tín hiệu nội bào bao gồm các yếu tố phiên mã như protein liên kết yếu tố phản ứng cAMP.
Từ khóa
#tâm thần phân liệt; axit béo không bão hòa đa n−3; yếu tố thần kinh có nguồn gốc từ não; BDNF; giả dược; nghiên cứu lâm sàngTài liệu tham khảo
Addington J, Shah H, Liu L, Addington D (2014) Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis. 153:64–67. https://doi.org/10.1016/j.schres.2013.12.014
Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154. https://doi.org/10.1001/archgenpsychiatry.2009.192
Atake K, Nakamura T, Ueda N, Hori H, Katsuki A, Yoshimura R (2018) The impact of aging, psychotic symptoms, medication, and brain-derived neurotrophic factor on cognitive impairment in Japanese chronic schizophrenia patients. Front Psychiatry 9:232. https://doi.org/10.3389/fpsyt.2018.00232
Bak DH, Zhang E, Yi M-H, Kim DK, Lim K, Kim JJ, Kim DW (2015) High omega3-polyunsaturated fatty acids in fat-1 mice prevent streptozotocin-induced Purkinje cell degeneration through BDNF-mediated autophagy. Sci Rep 5:15465. https://doi.org/10.1038/srep15465
Beilharz JE, Kaakoush NO, Maniam J, Morris MJ (2016) The effect of short-term exposure to energy-matched diets enriched in fat or sugar on memory, gut microbiota and markers of brain inflammation and plasticity. Brain Behav Immun 57:304–313. https://doi.org/10.1016/j.bbi.2016.07.151
Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, McGorry PD (2008) Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 33:2467–2473. https://doi.org/10.1038/sj.npp.1301628
Bouckaert F, Dols A, Emsell L, de Winter FL, Vansteelandt K, Claes L, Sunaert S, Stek M, Sienaert P, Vandenbulcke M (2016) Relationship between hippocampal volume, serum BDNF, and depression severity following electroconvulsive therapy in late-life depression. Neuropsychopharmacology 41:2741–2748. https://doi.org/10.1038/npp.2016.86
Caldieraro MA, Vares EA, Souza LH, Spanemberg L, Guerra TA, Wollenhaupt-Aguiar B, Ferrari P, Nierenberg AA, Fleck MP (2017) Illness severity and biomarkers in depression: using a unidimensional rating scale to examine BDNF. Compr Psychiatry 75:46–52. https://doi.org/10.1016/j.comppsych.2017.02.014
Cargnin S, Massarotti A, Terrazzino S (2016) BDNF Val66Met and clinical response to antipsychotic drugs: a systematic review and meta-analysis. Eur Psychiatry 33:45–53. https://doi.org/10.1016/j.eurpsy.2015.12.001
Choi J-E, Park Y (2017) EPA and DHA, but not ALA, have antidepressant effects with 17β-estradiol injection via regulation of a neurobiological system in ovariectomized rats. J Nutr Biochem 49:101–109. https://doi.org/10.1016/j.jnutbio.2017.07.012
Cohen J (1988) Statistical power analysis for the behavioral sciences. L. Erlbaum Associates, Hillsdale
Crisafulli C, Drago A, Calabro M et al (2015) A molecular pathway analysis informs the genetic background at risk for schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 59:21–30. https://doi.org/10.1016/j.pnpbp.2014.12.009
Dehghan M, Ilow R, Zatonska K, Szuba A, Zhang X, Mente A, Regulska-Ilow B (2012) Development, reproducibility and validity of the food frequency questionnaire in the Poland arm of the Prospective Urban and Rural Epidemiological (PURE) study. J Hum Nutr Diet 25:225–232. https://doi.org/10.1111/j.1365-277X.2012.01240.x
Dong Y, Xu M, Kalueff AV, Song C (2017) Dietary eicosapentaenoic acid normalizes hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central interleukin-1beta administration. Eur J Nutr:1–11. https://doi.org/10.1007/s00394-017-1462-7
Fang M-S, Li X, Qian H, Zeng K, Ye M, Zhou YJ, Li H, Wang XC, Li Y (2017) ω-3PUFAs prevent MK-801-induced cognitive impairment in schizophrenic rats via the CREB/BDNF/TrkB pathway. J Huazhong Univ Sci Technol Med Sci 37:491–495. https://doi.org/10.1007/s11596-017-1762-4
Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, Nardin P, Gonçalves CA (2015) Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry 20:1108–1119. https://doi.org/10.1038/mp.2014.117
Friedman LM, Furberg CD, DeMets DL (2010) Fundamentals of clinical trials. Springer New York, New York
Funk AJ, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2012) Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology 37:896–905. https://doi.org/10.1038/npp.2011.267
Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen V, Gomez-Plascencia J, Ramos-Zuniga R, Gonzalez-Perez O (2016) Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders. Cytokine Growth Factor Rev 32:85–96. https://doi.org/10.1016/j.cytogfr.2016.08.004
Gama CS, Canever L, Panizzutti B, Gubert C, Stertz L, Massuda R, Pedrini M, de Lucena DF, Luca RD, Fraga DB, Heylmann AS, Deroza PF, Zugno AI (2012) Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophr Res 141:162–167. https://doi.org/10.1016/j.schres.2012.08.002
Gao H, Yan P, Zhang S, Huang H, Huang F, Sun T, Deng Q, Huang Q, Chen S, Ye K, Xu J, Liu L (2016) Long-term dietary alpha-linolenic acid supplement alleviates cognitive impairment correlate with activating hippocampal CREB signaling in natural aging rats. Mol Neurobiol 53:4772–4786. https://doi.org/10.1007/s12035-015-9393-x
Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ (2011) Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 16:960–972. https://doi.org/10.1038/mp.2010.88
Grillo RW, Ottoni GL, Leke R et al (2007) Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 41:31–35. https://doi.org/10.1016/j.jpsychires.2006.01.005
Guy W (1976) Guy—the clinical global impression scale. In: ECDEU assessment manual for psychopharmacology—revised, pp 218–222
Hammamieh R, Chakraborty N, Gautam A, Miller SA, Muhie S, Meyerhoff J, Jett M (2014) Transcriptomic analysis of the effects of a fish oil enriched diet on murine brains. PLoS One 9:e90425. https://doi.org/10.1371/journal.pone.0090425
Heitz U, Papmeyer M, Studerus E, Egloff L, Ittig S, Andreou C, Vogel T, Borgwardt S, Graf M, Eckert A, Riecher-Rössler A (2018) Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. World J Biol Psychiatry:1–10. https://doi.org/10.1080/15622975.2018.1462532
Hori H, Yoshimura R, Katsuki A, Atake K, Nakamura J (2014) Relationships between brain-derived neurotrophic factor, clinical symptoms, and decision-making in chronic schizophrenia: data from the Iowa Gambling Task. Front Behav Neurosci 8:116–118. https://doi.org/10.3389/fnbeh.2014.00417
Hori H, Yoshimura R, Katsuki A, Atake K, Igata R, Konishi Y, Beppu H, Tominaga H (2017) Blood biomarkers predict the cognitive effects of aripiprazole in patients with acute schizophrenia. Int J Mol Sci 18:568. https://doi.org/10.3390/ijms18030568
Huang TL (2013) Effects of antipsychotics on the BDNF in schizophrenia. Curr Med Chem 20:345–350
Igarashi M, Santos RA, Cohen-Cory S (2015) Impact of maternal n-3 polyunsaturated fatty acid deficiency on dendritic arbor morphology and connectivity of developing Xenopus laevis central neurons in vivo. J Neurosci 35:6079–6092. https://doi.org/10.1523/JNEUROSCI.4102-14.2015
Igolkina AA, Armoskus C, Newman JRB, Evgrafov OV, McIntyre LM, Nuzhdin SV, Samsonova MG (2018) Analysis of gene expression variance in schizophrenia using structural equation modeling. Front Mol Neurosci 11:192. https://doi.org/10.3389/fnmol.2018.00192
Jevtović S, Karlović D, Mihaljevic-Peles A et al (2011) Serum brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression. Psychiatr Danub 23:363–369
Jiang H, Chen S, Li C, Lu N, Yue Y, Yin Y, Zhang Y, Zhi X, Zhang D, Yuan Y (2017) The serum protein levels of the tPA-BDNF pathway are implicated in depression and antidepressant treatment. Transl Psychiatry 7:e1079. https://doi.org/10.1038/tp.2017.43
Jones SH, Thornicroft G, Coffey M, Dunn G (1995) A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166:654–659
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276. https://doi.org/10.1093/schbul/13.2.261
Keleshian VL, Kellom M, Kim H-W, Taha AY, Cheon Y, Igarashi M, Rapoport SI, Rao JS (2014) Neuropathological responses to chronic NMDA in rats are worsened by dietary n-3 PUFA deprivation but are not ameliorated by fish oil supplementation. PLoS One 9:e95318. https://doi.org/10.1371/journal.pone.0095318
Kudlek Mikulic S, Mihaljevic-Peles A, Sagud M, Bajs Janovic M, Ganoci L, Grubisin J, Kuzman Rojnic M, Vuksan Cusa B, Bradaš Z, Božina N (2017) Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. Nord J Psychiatry 71:513–520. https://doi.org/10.1080/08039488.2017.1340518
Lang UE, Jockers-Scherübl MC, Hellweg R (2004) State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J Neural Transm 111:387–411. https://doi.org/10.1007/s00702-003-0100-0
Li J, Ye F, Xiao W, Tang X, Sha W, Zhang X, Wang J (2016) Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia. Eur Psychiatry 36:23–28. https://doi.org/10.1016/j.eurpsy.2016.03.005
Martinez-Cengotitabengoa M, MacDowell KS, Alberich S et al (2016) BDNF and NGF signalling in early phases of psychosis: relationship with inflammation and response to antipsychotics after 1 year. Schizophr Bull 42:142–151. https://doi.org/10.1093/schbul/sbv078
Matsuoka Y, Nishi D, Hamazaki K, Yonemoto N, Matsumura K, Noguchi H, Hashimoto K, Hamazaki T (2015a) Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: a randomized, placebo-controlled trial. J Clin Psychiatry 76:e1015–e1022. https://doi.org/10.4088/JCP.14m09260
Matsuoka Y, Nishi D, Tanima Y, Itakura M, Kojima M, Hamazaki K, Noguchi H, Hamazaki T (2015b) Serum pro-BDNF/BDNF as a treatment biomarker for response to docosahexaenoic acid in traumatized people vulnerable to developing psychological distress: a randomized controlled trial. Transl Psychiatry 5:e596. https://doi.org/10.1038/tp.2015.89
McGorry PD, Nelson B, Markulev C et al (2016) Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry 74:19–27. https://doi.org/10.1001/jamapsychiatry.2016.2902
Mohammadi A, Amooeian VG, Rashidi E (2018a) Dysfunction in brain-derived neurotrophic factor signaling pathway and susceptibility to schizophrenia, Parkinson’s and Alzheimer’s diseases. Curr Gene Ther 18:45–63. https://doi.org/10.2174/1566523218666180302163029
Mohammadi A, Rashidi E, Amooeian VG (2018b) Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. Psychiatry Res 265:25–38. https://doi.org/10.1016/j.psychres.2018.04.036
Nascimento LFR, Souza GFP, Morari J, Barbosa GO, Solon C, Moura RF, Victório SC, Ignácio-Souza LM, Razolli DS, Carvalho HF, Velloso LA (2016) N-3 fatty acids induce neurogenesis of predominantly POMC-expressing cells in the hypothalamus. Diabetes 65:673–686. https://doi.org/10.2337/db15-0008
Nieto R, Kukuljan M, Silva H (2013) BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry 4:45. https://doi.org/10.3389/fpsyt.2013.00045
Nikolac Perkovic M, Nedic Erjavec G, Zivkovic M, Sagud M, Uzun S, Mihaljevic-Peles A, Kozumplik O, Muck-Seler D, Pivac N (2014) Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacology 231:3757–3764. https://doi.org/10.1007/s00213-014-3515-4
Nurjono M, Lee J, Chong S-A (2012) A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clin Psychopharmacol Neurosci 10:61–70. https://doi.org/10.9758/cpn.2012.10.2.61
Pawełczyk T, Grancow M, Kotlicka-Antczak M, Trafalska E, Gębski P, Szemraj J, Żurner N, Pawełczyk A (2015) Omega-3 fatty acids in first-episode schizophrenia—a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. 15:97. https://doi.org/10.1186/s12888-015-0473-2
Pawełczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawełczyk A (2016) A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 73:34–44. https://doi.org/10.1016/j.jpsychires.2015.11.013
Pedrini M, Chendo I, Grande I, Lobato MI, Belmonte-de-Abreu PS, Lersch C, Walz J, Kauer-Sant’Anna M, Kapczinski F, Gama CS (2011) Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett 491:207–210. https://doi.org/10.1016/j.neulet.2011.01.039
Peet M, Horrobin DF, E-E Multicentre Study Group (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 36:7–18. https://doi.org/10.1016/S0022-3956(01)00048-6
Pirildar S, Gönül AS, Taneli F, Akdeniz F (2004) Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuro-Psychopharmacol Biol Psychiatry 28:709–713. https://doi.org/10.1016/j.pnpbp.2004.05.008
Pudell C, Vicente BA, Delattre AM, Carabelli B, Mori MA, Suchecki D, Machado RB, Zanata SM, Visentainer JV, de Oliveira Santos O Jr, Lima MMS, Ferraz AC (2014) Fish oil improves anxiety-like, depressive-like and cognitive behaviors in olfactory bulbectomised rats. Eur J Neurosci 39:266–274. https://doi.org/10.1111/ejn.12406
Rao JS, Ertley RN, Lee H-J, DeMar JC, Arnold JT, Rapoport SI, Bazinet RP (2007) N-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 12:36–46. https://doi.org/10.1038/sj.mp.4001888
Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, Katsafouros K, Lykouras L (2010) Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 11:251–255. https://doi.org/10.3109/15622970802182733
Rizos E, Papathanasiou MA, Michalopoulou PG, Laskos E, Mazioti A, Kastania A, Vasilopoulou K, Nikolaidou P, Margaritis D, Papageorgiou C, Liappas I (2014) A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia. PLoS One 9:e87997. https://doi.org/10.1371/journal.pone.0087997
Savitz DA, Olshan AF (1995) Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol 142:904–908
Sugai T, Kawamura M, Iritani S et al (2004) Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann N Y Acad Sci 1025:84–91. https://doi.org/10.1196/annals.1316.011
Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY (2005) Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382:27–32. https://doi.org/10.1016/j.neulet.2005.02.054
Thompson Ray M (2011) Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 36:195–203. https://doi.org/10.1503/jpn.100048
Tiraboschi E, Tardito D, Kasahara J, Moraschi S, Pruneri P, Gennarelli M, Racagni G, Popoli M (2004) Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology 29:1831–1840. https://doi.org/10.1038/sj.npp.1300488
Trevizol F, Dias VT, Roversi K, Barcelos RCS, Kuhn FT, Roversi K, Pase CS, Golombieski R, Veit JC, Piccolo J, Emanuelli T, Rocha JBT, Bürger ME (2015a) Cross-generational trans fat intake modifies BDNF mRNA in the hippocampus: impact on memory loss in a mania animal model. Hippocampus 25:556–565. https://doi.org/10.1002/hipo.22391
Trevizol F, Roversi K, Dias VT, Roversi K, Barcelos RCS, Kuhn FT, Pase CS, Golombieski R, Veit JC, Piccolo J, Pochmann D, Porciúncula LO, Emanuelli T, Rocha JBT, Bürger ME (2015b) Cross-generational trans fat intake facilitates mania-like behavior: oxidative and molecular markers in brain cortex. Neuroscience 286:353–363. https://doi.org/10.1016/j.neuroscience.2014.11.059
Valiente-Gómez A, Amann BL, Mármol F, Oliveira C, Messeguer A, Lafuente A, Pomarol-Clotet E, Bernardo Arroyo M (2014) Comparison of serum BDNF levels in deficit and nondeficit chronic schizophrenia and healthy controls. Psychiatry Res 220:197–200. https://doi.org/10.1016/j.psychres.2014.08.039
Venna VR, Deplanque D, Allet C, Belarbi K, Hamdane M, Bordet R (2009) PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus. Psychoneuroendocrinology 34:199–211. https://doi.org/10.1016/j.psyneuen.2008.08.025
Wu A, Ying Z, Gomez-Pinilla F (2004) Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. 21:1457–1467. https://doi.org/10.1089/neu.2004.21.1457 https://home.liebertpub.com/neu
Xiu MH, Hui L, Dang YF, de Hou T, Zhang CX, Zheng YL, Chen DC, Kosten TR, Zhang XY (2009) Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry 33:1508–1512. https://doi.org/10.1016/j.pnpbp.2009.08.011
Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J (2010) Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 11:256–261. https://doi.org/10.3109/15622970802309617
Zhang Y, Fang X, Fan W, et al (2018) Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study. Psychopharmacology (Berl) 235:1191–1198. https://doi.org/10.1007/s00213-018-4835-6
Zhou C, Zhong J, Zou B, Fang L, Chen J, Deng X, Zhang L, Zhao X, Qu Z, Lei Y, Lei T (2017) Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression. PLoS One 12:e0172270. https://doi.org/10.1371/journal.pone.0172270
Zugno AI, Canever L, Mastella G et al (2015) Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia. An Acad Bras Cienc 87:1475–1486. https://doi.org/10.1590/0001-3765201520140714